The Food and Drug Administration has accepted the new drug application for a proposed nausea drug from BioDelivery Sciences International (BDSI) and is now reviewing it, BDSI says.
The review process could take up to 10 months. BDSI filed the drug application in April.
The drug under consideration is called Emezine and is a proposed treatment for nausea and vomiting. According to BDSI, Emezine is believed to be the first such drug to be delivered orally as a pill rather than as an injection of suppository.
BDSI has licensed the drug from Reckitt Benckiser Healthcare, which is based in the United Kingdom.